Brooke Fiala

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9879648/publications.pdf Version: 2024-02-01



RROOKE FIALA

#	Article	IF	CITATIONS
1	Epitope-focused immunogen design based on the ebolavirus glycoprotein HR2-MPER region. PLoS Pathogens, 2022, 18, e1010518.	2.1	5
2	Adjuvanting a subunit SARS-CoV-2 vaccine with clinically relevant adjuvants induces durable protection in mice. Npj Vaccines, 2022, 7, .	2.9	32
3	Immunization with a self-assembling nanoparticle vaccine displaying EBV gH/gL protects humanized mice against lethal viral challenge. Cell Reports Medicine, 2022, 3, 100658.	3.3	12
4	Dynamics of Neutralizing Antibody Titers in the Months After Severe Acute Respiratory Syndrome Coronavirus 2 Infection. Journal of Infectious Diseases, 2021, 223, 197-205.	1.9	216
5	Functional SARS-CoV-2-Specific Immune Memory Persists after Mild COVID-19. Cell, 2021, 184, 169-183.e17.	13.5	580
6	Adjuvanting a subunit COVID-19 vaccine to induce protective immunity. Nature, 2021, 594, 253-258.	13.7	253
7	Elicitation of broadly protective sarbecovirus immunity by receptor-binding domain nanoparticle vaccines. Cell, 2021, 184, 5432-5447.e16.	13.5	131
8	Engineered SARS-CoV-2 receptor binding domain improves manufacturability in yeast and immunogenicity in mice. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	68
9	Elicitation of Potent Neutralizing Antibody Responses by Designed Protein Nanoparticle Vaccines for SARS-CoV-2. Cell, 2020, 183, 1367-1382.e17.	13.5	420
10	Enhancing and shaping the immunogenicity of native-like HIV-1 envelope trimers with a two-component protein nanoparticle. Nature Communications, 2019, 10, 4272.	5.8	149
11	Induction of Potent Neutralizing Antibody Responses by a Designed Protein Nanoparticle Vaccine for Respiratory Syncytial Virus. Cell, 2019, 176, 1420-1431.e17.	13.5	339